You are here

Home » Pharmacology and Drug Treatment » Phase 3, Randomized, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System (20 Mcg/Day) and Mirena® for Long-Term, Reversible Contraception up to Five Years

Phase 3, Randomized, Multi-Center, Open-Label Study of a Levonorgestrel-Releasing Intrauterine System (20 Mcg/Day) and Mirena® for Long-Term, Reversible Contraception up to Five Years

3/31/10 - 9/30/17

Investigator: Philip D. Darney, MD, MS

Sponsor: Medicines360

Location(s): United States

Description

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who request long-term, reversible contraception.